Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy. - Wikidata - wikimedia - TriplyDB

Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy.

Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy.

http://www.wikidata.org/entity/Q37587308

about

Phosphoinositide 3-Kinase-Dependent Signalling Pathways in Cutaneous Squamous Cell Carcinomas.Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers.Pharmacologic characterization of SHR8443, a novel dual inhibitor of phosphatidylinositol 3-kinase and mammalian target of rapamycin.Viral Oncology: Molecular Biology and Pathogenesis.The prognostic value of PI3K mutational status in breast cancer: a meta-analysis.The effects of PI3K-mediated signalling on glioblastoma cell behaviour.PTEN/PTENP1: 'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy.Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways.Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer.

P2860

Q38684394-9E2C665E-DA5D-41D3-991C-9E4F58316A33 Q45790068-A78A8117-3E77-43A2-A53D-4CFE67577156 Q47217432-B8145CDB-4D90-4A9F-A436-250F444029A8 Q47571734-A6F1B973-48F0-4636-9A71-3A5F0DC1ACDD Q47725954-5310C55A-58C0-453B-81D0-5F8EA470F55E Q47945880-9FDA6C47-EB05-4A7E-9BD7-CA6D6CF2929C Q49887901-B8C45D02-643A-4861-8080-09DF29418B6B Q54917620-5610F01D-B105-48DB-B04E-6B8AB848883C Q55206758-45BC56FC-BFA6-4540-B840-F0CD9E0BC57A

P2860

Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy.

http://www.wikidata.org/entity/Q37587308

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 29 July 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy.

@en

Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy.

@nl

type

label

Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy.

@en

Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy.

@nl

prefLabel

Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy.

@en

Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy.

@nl

P1433

Q37587308-DA95C8D3-55AE-433E-9FC8-786C3716742C

P1476

Q37587308-F794454A-AD52-40CE-A073-6BFBFB846E82

P2093

Q37587308-03DC845D-C790-4D63-81BD-C63957131F59

Q37587308-5D1B86F4-3D6B-44F6-93A4-2C2B3BACC96B

Q37587308-ABEA835C-4546-45A4-8F03-E482EB262694

P2860

Q37587308-001C3DEA-4CCE-4651-BD50-95A3B2B18306

Q37587308-04BDA6CD-8E41-46CC-92A9-B0DA750DB9FA

Q37587308-0A6F48C5-9A03-4CFD-A09E-26587FF8A924

Q37587308-0BEA4734-0E02-496F-AD8C-04C52DE2B692

Q37587308-120365D8-A283-489B-95B0-36B65469954F

Q37587308-187DCD26-F131-4420-80D1-EA993DCF2364

Q37587308-1BCBB3D7-0B54-4705-9516-3800E8E341BA

Q37587308-1E87A50F-3DEE-4912-A1BD-9BBF87E9437B

Q37587308-21472109-7B2E-4574-9519-3E1C9FE28D42

Q37587308-2446DF24-A41F-4C49-8B0C-9B7D410CD650

P304

Q37587308-EDD7A9EE-EE72-41DE-B8FA-932D8A281A16

P31

Q37587308-A7F988FD-2D12-48CA-958B-9D2D39993B90

P356

Q37587308-5578A480-97FE-4BC7-8E36-97FCE3B9C616

P433

Q37587308-4FB8152F-3CFC-4556-91B8-6F7EB1B5C7C3

P478

Q37587308-79D352D7-5C62-455E-98A5-02134399EF43

P577

Q37587308-5D7F18A7-C614-4DE2-ABFE-95DA400895E7

P698

Q37587308-93B46435-13EC-4000-8632-49E5C879E8FA

P932

Q37587308-FCF7BE5D-49FE-4835-BC44-92E56767D611

P356

J.APSB.2016.07.006

P1433

Acta pharmaceutica Sinica B

P1476

Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy.

@en

P2093

Dexin Kong

http://www.w3.org/2001/XMLSchema#string

Wennan Zhao

http://www.w3.org/2001/XMLSchema#string

Yuling Qiu

http://www.w3.org/2001/XMLSchema#string

P2860

PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?

P110delta, a novel phosphoinositide 3-kinase in leukocytes

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

P304

27-37

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.APSB.2016.07.006

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28119806

http://www.w3.org/2001/XMLSchema#string

P932

5237710

http://www.w3.org/2001/XMLSchema#string